Viiv Healthcare

This study tests a new long-acting injectable drug called VH4524184 in healthy adults to see if it is safe and how the body handles it. The goal is to find a dose that could one day help control HIV with fewer shots. About 268 volunteers will receive either the drug or a placebo …

This study tests a long-acting injectable HIV medication (CAB LA + RPV LA) in people whose virus is still detectable despite taking daily oral pills. About 332 participants will either get the shots or continue standard oral therapy. The goal is to see if the injections can bette…

This study looks at whether the HIV drug cabotegravir is safe for newborns who were exposed to HIV during birth. About 44 healthy babies will receive the drug either by mouth or injection. The goal is to find the right dose and check for side effects, helping to protect these inf…

This study is testing a new experimental drug called VH4524184 for people with HIV-1 who have never taken HIV medication before. About 150 adults will receive either a low or high dose of VH4524184 along with two standard HIV drugs (emtricitabine and tenofovir alafenamide), or a …

This early-stage study is testing a long-acting injectable HIV prevention drug called cabotegravir, combined with an enzyme (rHuPH20) that helps the drug spread under the skin. The goal is to see if this combination is safe and how the body processes it in 214 healthy adults. Res…

This study is checking the long-term safety and effectiveness of a long-acting injectable drug called cabotegravir (CAB LA) for preventing HIV. It includes about 3,500 people who already received CAB LA in earlier HIV prevention studies. Participants will continue getting the sho…

This early-stage study tests a new long-acting injectable drug, VH4011499, in 168 healthy adults without HIV. The goal is to see if it is safe and how the body processes it, as a potential future option for HIV prevention. Participants receive one or more doses of the drug or a p…